We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · September 24, 2020

Abemaciclib Plus Endocrine Therapy for Adjuvant Treatment of HR+, HER2−, Node+, High-Risk, Early Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
J. Clin. Oncol 2020 Sep 20;[EPub Ahead of Print], SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, JL Martinez Rodriguez, M Campone, E Hamilton, J Sohn, V Guarneri, M Okada, F Boyle, P Neven, J Cortés, J Huober, A Wardley, SM Tolaney, I Cicin, IC Smith, M Frenzel, D Headley, R Wei, B San Antonio, M Hulstijn, J Cox, J O'Shaughnessy, P Rastogi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading